IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 316 filers reported holding IONIS PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is 0.96 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $12,238 | -19.5% | 269,800 | -27.2% | 0.02% | -4.5% |
Q2 2023 | $15,202 | -33.2% | 370,500 | -41.8% | 0.02% | -26.7% |
Q1 2023 | $22,742 | -48.9% | 636,314 | -46.0% | 0.03% | -50.8% |
Q4 2022 | $44,524 | -99.9% | 1,178,814 | +35.9% | 0.06% | +13.0% |
Q3 2022 | $38,379,000 | +68.6% | 867,714 | +41.1% | 0.05% | +100.0% |
Q2 2022 | $22,760,000 | +355.5% | 614,814 | +355.7% | 0.03% | +350.0% |
Q1 2022 | $4,997,000 | -28.9% | 134,914 | -41.5% | 0.01% | -33.3% |
Q4 2021 | $7,024,000 | +114.3% | 230,814 | +136.2% | 0.01% | +125.0% |
Q3 2021 | $3,277,000 | -89.4% | 97,714 | -87.4% | 0.00% | -89.7% |
Q2 2021 | $30,971,000 | +17.3% | 776,414 | +32.2% | 0.04% | +18.2% |
Q1 2021 | $26,410,000 | -37.3% | 587,414 | -21.2% | 0.03% | -28.3% |
Q4 2020 | $42,142,000 | -39.5% | 745,348 | -49.2% | 0.05% | -34.3% |
Q3 2020 | $69,617,000 | -32.6% | 1,467,167 | -16.3% | 0.07% | -21.3% |
Q2 2020 | $103,349,000 | +29.5% | 1,752,867 | +3.8% | 0.09% | +14.1% |
Q1 2020 | $79,828,000 | -35.2% | 1,688,411 | -17.2% | 0.08% | -17.9% |
Q4 2019 | $123,159,000 | +13.4% | 2,038,711 | +12.4% | 0.10% | +3.3% |
Q3 2019 | $108,617,000 | -3.7% | 1,813,011 | +3.3% | 0.09% | -7.1% |
Q2 2019 | $112,814,000 | +671.7% | 1,755,311 | +419.9% | 0.10% | +1137.5% |
Q2 2018 | $14,618,000 | +45.6% | 337,628 | +48.3% | 0.01% | -27.3% |
Q1 2018 | $10,038,000 | +139.5% | 227,714 | +176.3% | 0.01% | +120.0% |
Q2 2017 | $4,192,000 | -66.7% | 82,414 | -73.7% | 0.01% | -72.2% |
Q1 2017 | $12,591,000 | -41.4% | 313,214 | -30.3% | 0.02% | -47.1% |
Q4 2016 | $21,500,000 | +113.5% | 449,514 | +63.6% | 0.03% | +88.9% |
Q3 2016 | $10,069,000 | +136.1% | 274,814 | +50.1% | 0.02% | +125.0% |
Q2 2016 | $4,264,000 | +77.2% | 183,100 | +208.2% | 0.01% | +60.0% |
Q1 2016 | $2,406,000 | -71.3% | 59,400 | -56.1% | 0.01% | -72.2% |
Q4 2015 | $8,380,000 | – | 135,314 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tweedy, Browne Co LLC | 3,541,136 | $133,749 | 7.12% |
Bellevue Group AG | 9,743,900 | $368,027,103 | 4.88% |
M28 Capital Management LP | 126,300 | $4,770,351 | 4.55% |
Sicart Associates LLC | 246,258 | $9,301,165 | 3.28% |
Camber Capital Management LP | 1,925,000 | $72,707 | 2.49% |
Privium Fund Management B.V. | 148,807 | $5,557,941 | 2.11% |
Deep Track Capital, LP | 1,205,773 | $45,542,046 | 1.91% |
BVF INC/IL | 1,121,809 | $42,370,726 | 1.79% |
Orbimed Advisors | 1,993,600 | $75,298,272 | 1.44% |
Parkman Healthcare Partners LLC | 141,115 | $5,329,914 | 1.42% |